Diamond Blackfan Anemia (DBAAAS) Syndrome Therapeutics Market Future Scenario by 2033

 The Global Diamond-Blackfan Anemia (DBAAASE) Syndrome Therapeutics Market is predicted to exceed an impressive US$ 4.8 Billion in 2023, with a compound annual growth rate (CAGR) of 4.1% from 2023 to 2033.

Because 90% of infected individuals develop hematologic difficulties during their first year of life, a rise in the incidence of blood disorders catapulted the global diamond-blackfan anemia treatment market over the historical era.

Get Full Access @ https://www.futuremarketinsights.com/reports/diamond-blackfan-anemia-syndrome-therapeutics-market

 Moreover, growing government R&D support, changing lifestyles, and rapidly evolving technology are anticipated to propel market growth in the forecast period.

North America dominates the diamond-blackfan anaemia syndrome therapeutics market owing to the presence of major notable stakeholders, high expendable income, increased medical costs, and an established medical sector in this region. According to a report published by Clevel and Clinic, the DBA Registry of North America, a database containing data on people who have this disorder, 25% of people with DBA die before the age of 50 from affiliated medical disorders.

DBA UK is a registered charity (1083179) that is governed by a written constitution and run by appointed volunteer groups. They offer support, research, and hope to the DBA community by bringing families together to discuss their experiences, share the most recent health history, and raise funds to assist those with DBA in the United Kingdom.

Key Takeaways from the Market Study

  • Global DBAAASE syndrome therapeutics market to expand 1.5x from 2023 to 2033
  • By treatment, blood transfusions to experience a growth rate of 6.9%
  • Around 2 out of 5 DBAAASE syndrome therapeutics to happen across North America
  • Europe to emerge as an important contributor, expected to surge at a CAGR of 3.7%
  • Treatment through corticosteroids to gain equal traction as blood transfusions

“As medical science expands, treatments and therapies for a broad range of blood disorders is gaining major traction. This is boding well for the market on diamond blackfan anemia syndrome, with healthcare providers introducing a plethora of therapies and treatment approaches,” says an FMI analyst.

Key Market Players

Key players in the Diamond–Blackfan Anemia (DBA)/Aase Syndrome Therapeutics market are Sumitomo Corporation, Johnson & Johnson Private Limited, Novartis AG, Pfizer Inc, Sanofi, Merck KGaA, LEO Pharma A/S, Cipla Inc., GlaxoSmithKline plc, AstraZeneca, Abbott, Bayer AG.

  • In July 2021, AstraZeneca procured Alexion Pharmaceuticals, a global biotech company. With this acquisition, the company will be able to enter the market for rare disease medicines, ushering in a new chapter. Moreover, the acquisition strengthened AstraZeneca's scientific presence in immunology and would allow the company to continue to pioneer the discovery and development of medicines for patients with rare diseases using Alexion's new complement-biology system and robust pipeline.
  • In June 2022, Pfizer will collaborate with Sirana Pharma, a biotechnology company. The collaboration would help Pfizer recognize and validate a novel therapeutic concept for unique and severe bone diseases.

Key Segments Profiled in the Diamond–Blackfan Anemia (DBAAASE) Syndrome Therapeutics Market Industry Survey 

By Treatment:

  • Corticosteroids
  • Chelation Therapy
  • Blood Transfusions
  • Stem Cell Transplant
  • Others

By End User:

  • Hospitals
  • Clinics
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Comments

Post a Comment

Popular posts from this blog

Monoclonal Antibodies Market to touch US$ 647.01 Billion by 2032; applications abound in Oncology | FMI Report

Image
  Monoclonal Antibodies Market is projected to increase at a CAGR of 12% during the forecast period between 2022 and 2032, reaching a total of US$ 647.01 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 6.1%. Human mAbs offer efficient modulation in effector functions and are less immunogenic as compared to chimeric or humanized mAbs. Such antibodies can be produced through the use of phage display and hybridoma technologies in transgenic mice. As a result, with recent technological progress in genetic engineering, the production of fully human mAbs is anticipated to gain traction in the near future.  Get Full Access @ https://www.futuremarketinsights.com/reports/monoclonal-antibodies-market North America recorded the largest market share of 46.2% in 2021 due to the presence of a highly developed healthcare infrastructure, high patient awareness, and growth in cancer research pr
Read more

Companion Diagnostics Market Recent Trends, Dynamic Innovation in Technology & Insights 2032

Image
  The global Companion Diagnostics Market is expected to generate approximately US$ 5152.064939 million by 2032, up from US$ 2452.653722 million in 2022, at a CAGR of 7.1% during the forecast period. With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, FMI presents an extensive analysis on Companion Diagnostics market. To read more about this report, visit @ https://www.futuremarketinsights.com/reports/companion-diagnostics-market FMI offers insights into the market data on over 5000+ drugs for more than 100 countries, which further aids the research on current and upcoming market scenario for the Companion Diagnostics market. Our expert researchers and analysts for healthcare tracks the data of established players as well as new entrants in medical industry to provide an unbiased analysis for a sound and financial decision. Over the past decade, healthcare sector has been expanding remarkably, followi
Read more

Hospital Consumables Market is expected to reach valuation of US$ 853.2 Billion | FMI

  According to Future Market Insights' newly released Hospital Consumables market analysis report, global Hospital Consumables market sales in 2021 are expected to be US$ 346 billion. The estimated market growth of 12.5% between 2022 and 2032 is expected to be much greater than the previous trend. The consumables market is estimated to have a total revenue opportunity of US$ 853.2 billion. The increase in chronic diseases, medical operations, and the expanding older population are driving market expansion. To learn more about this report @ https://www.futuremarketinsights.com/reports/hospital-consumables-market With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, FMI presents an extensive analysis on Hospital Consumables market. FMI offers insights into the market data on over 5000+ drugs for more than 100 countries, which further aids the research on current and upcoming market scenario for the Hospita
Read more